| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/22/2008 | US7361674 7, 8 and 9-substituted tetracycline compounds |
| 04/22/2008 | US7361672 Pyrazoles, triazoles, or tetrazoles substituted with an aryl- or heteroarylcarbonylamino group and an aminocarbonylmethyl group: 5-chloro-thiophene-2-carboxylic acid (1-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-methyl}-1H-[1,2,4]triazol-3-yl)-amide; improved selectivity towards thrombin |
| 04/22/2008 | US7361671 E.g.,(6-Ethyl-3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrr (2,3-b)pyridin-1-yl)acetic acid; interacts with and inhibits aldose reductase; antidiabetic agents and diabetic complications; gout; hypoglycemic and antiarthritic |
| 04/22/2008 | US7361670 Amide derivatives as NMDA receptor antagonists |
| 04/22/2008 | US7361669 particularly useful for treating cardiovascular disease |
| 04/22/2008 | US7361668 Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors |
| 04/22/2008 | US7361667 Attention defect disorders; alcoholism; drug abuse; Parkinson's disease; anxiolytic agents; antidepressants |
| 04/22/2008 | US7361666 Ligands for cellular receptors, including opiate receptors; side effect reduction; base structure is a saturated nitrogen-containing ring substituted with a tertiary amide that is N-substituted with an arylalkyl group |
| 04/22/2008 | US7361665 For therapy of inflammatory disease, autoimmune disease, destructive bone disorder, proliferative disorder, infectious disease, neurodegenerative disease, allergy, reperfusion/ischemia in stroke, heart attack, hypoxia |
| 04/22/2008 | US7361664 For therapy of cancer, hyperparathyroidism, vascular calcification, bone disease, renal failure or kidney stones, psoriasis |
| 04/22/2008 | US7361663 N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa |
| 04/22/2008 | US7361662 Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same |
| 04/22/2008 | US7361661 3-isobutyl-8-(6-methoxy-isoquinolin-4-ylmethyl)-1-methyl-3, 7-dihydro-purine-2,6-dione; sexual dysfunction, premature labour, dysmenorrhoea, benign prostatic hyperplasia, bladder outlet obstruction, incontinence, (Prinzmetal) angina, hipotensive agent |
| 04/22/2008 | US7361660 Chemical compounds |
| 04/22/2008 | US7361659 7-Difluoromethyl-5-(4-trifluoromethyl-phenyl)-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (2-chloro-5-sulfamoyl-thiophen-3-yl)-amide; metabotropic glutamate receptors antagonist; anxiolitic, analgesic, hyperglycemic agent; absorption, advantages in pharmacokinetics in distribution transport to the brain |
| 04/22/2008 | US7361658 2-acylaminothiazole derivative or salt thereof |
| 04/22/2008 | US7361657 Drugs for treatment of respiratory syncytial virus and salt formation |
| 04/22/2008 | US7361656 Prenyl transferase inhibitors |
| 04/22/2008 | US7361655 Pharmaceutically effective compounds |
| 04/22/2008 | US7361654 Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| 04/22/2008 | US7361652 βd-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
| 04/22/2008 | US7361651 Procoralan; brandycardial agent: angina pectoris, myocardial infarct, heart failure, myocardial ischaemia, supraventricular rhythm disturbances; stability and processability |
| 04/22/2008 | US7361650 γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
| 04/22/2008 | US7361649 β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
| 04/22/2008 | US7361648 1-(4-{ethyl-[2-(4-methanesulfonylphenyl)-1-methylethyl]amino}butyl)-4-methanesulfonyl-[1,4]diazepan-2-one; repiratory system disorders: asthma and chronic obstructive pulmonary disease; nervous system, muscular,urogenital, gastrointestinal disorders; antiallergens; side effect reduction |
| 04/22/2008 | US7361647 hydroquinone derivatives of the Geldanamycin family; heat shock protein (chaperone) Hsp90 antagonist; improved solubility and air stability; antiproliferative and anticarcinogenic agents |
| 04/22/2008 | US7361646 Methods for treating gastroesophageal reflux disease |
| 04/22/2008 | US7361645 Androgenic 7-substituted 11-halogen steroids |
| 04/22/2008 | US7361644 Glycomimetics linked to a benzyl amino sulfonic acid (BASA) and combined with another diagnostic or therapeutic agent; inhibition of tissue transplant rejection and cell adhesion |
| 04/22/2008 | US7361643 Administering a nucleoside, such as tunicamycin; administering glucosamine |
| 04/22/2008 | US7361642 Development of hematological changes can be offset by recombinant growth hormone therapy; increases red blood cell and hemoglobin values |
| 04/22/2008 | US7361641 Methods and compositions for genomic modification |
| 04/22/2008 | US7361640 Stable lipid-comprising drug delivery complexes and methods for their production |
| 04/22/2008 | US7361639 Gene therapy agent for Haemophilia B and its preparation method |
| 04/22/2008 | US7361511 Comparing gene expression levels in normal and tumor cells, diagnosis, treating with an antisense oligonucleotide, and monitoring results |
| 04/22/2008 | US7361502 Nucleic acid molecule encoding a neuronal serine-threonine protein kinase |
| 04/22/2008 | US7361459 Antiviral inhibition of capsid proteins |
| 04/22/2008 | US7361370 Extracts of Tribulus terrestris, Epimedium koreanum, Cinnamon cassia, arginine, and carrier/excipient |
| 04/22/2008 | US7361365 Vermin repellent |
| 04/22/2008 | US7361362 Emulsion composition |
| 04/22/2008 | US7361345 monoclonal antibody prevents the growth or differentiation of the B cell; secreted by the hybridoma; therapy of autoimmune diseases, sytematic lupus erythematosus, primary biliary cirrhosis, and idiopathic thrombocytopenic purpura; biodrug |
| 04/22/2008 | US7361340 Specifically recognizing human oculospanin and having cytotoxic activity against cancer cells, cancer therapy |
| 04/22/2008 | US7361339 Methods for reducing morality associated with acute myocardial infarction |
| 04/22/2008 | CA2448864C Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer |
| 04/22/2008 | CA2438213C Modulated release particles for aerosol delivery |
| 04/22/2008 | CA2437603C Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid |
| 04/22/2008 | CA2406042C Apparatus for generating an aerosol |
| 04/22/2008 | CA2400447C Kinase inhibitors |
| 04/22/2008 | CA2388759C Substituted piperazine derivatives, the preparation thereof and their use as medicaments |
| 04/22/2008 | CA2362697C Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, method for producing them and their use as medicaments |
| 04/22/2008 | CA2359813C Nicotine mucosal spray |
| 04/22/2008 | CA2354619C Intermediates and process for producing fluorine-containing amino acid compound by using the same |
| 04/22/2008 | CA2350137C New piperazine and di-dehydropiperidine compounds |
| 04/22/2008 | CA2321687C Combination of a selective nmda nr2b antagonist and a cox-2 inhibitor |
| 04/22/2008 | CA2318349C Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use |
| 04/22/2008 | CA2302669C Piperidinylmethyloxazolidinone derivative |
| 04/22/2008 | CA2299366C Use of xanthophylls for improvement of duration of muscle function or treatment of muscle disorders or diseases |
| 04/22/2008 | CA2297082C Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides |
| 04/22/2008 | CA2288743C Pourable alginate compositions |
| 04/22/2008 | CA2280183C Method of treating dry eye disease with purinergic receptor agonists |
| 04/22/2008 | CA2279963C Dinucleotides and their use |
| 04/22/2008 | CA2279932C 3'-n-oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives |
| 04/22/2008 | CA2270777C Quinoline and quinazoline derivatives having corticotropin releasing factor (crf) antagonist activity |
| 04/22/2008 | CA2265993C Novel antimicrobial cosmetic compositions |
| 04/22/2008 | CA2259781C Low tack lotion, gels and creams |
| 04/22/2008 | CA2250600C Oral analgesic compositions |
| 04/22/2008 | CA2239582C A new therapeutic use for glycine |
| 04/22/2008 | CA2225807C Use of lamellarin-class alkaloids in methods of treatment |
| 04/22/2008 | CA2219065C Ophthalmic carrier solution |
| 04/22/2008 | CA2200195C Use of aromatase inhibitors for the production of a pharmaceutical agentfor treating a relative androgen deficiency in men |
| 04/22/2008 | CA2180816C 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients |
| 04/22/2008 | CA2174737C Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents |
| 04/22/2008 | CA2164770C Sodium hyaluronate viscous solutions for use as masking fluid in therapeutic photokeratectomy by means of excimer laser |
| 04/22/2008 | CA2150642C Tablet, capsule, or granule comprising desogestrel |
| 04/22/2008 | CA2129542C Pharmaceutical preparation based on rhamnolipid |
| 04/22/2008 | CA2112395C Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| 04/18/2008 | CA2606971A1 Method for producing ginseng fruit and ginseng flower stalk with high content of ginsenoside |
| 04/17/2008 | WO2008046087A2 Spiro compounds and their uses as therapeutic agents |
| 04/17/2008 | WO2008046084A2 Spiroheterocyclic compounds and their uses as therapeutic agents |
| 04/17/2008 | WO2008046071A2 Compounds and methods of treating metabolic syndrome and inflammation |
| 04/17/2008 | WO2008046065A1 Spiroheterocyclic compounds and their uses as therapeutic agents |
| 04/17/2008 | WO2008046052A1 Pharmaceutical formulations |
| 04/17/2008 | WO2008046049A1 Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| 04/17/2008 | WO2008046038A2 Intranasal therapeutics for neuroprotection |
| 04/17/2008 | WO2008046014A1 Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors |
| 04/17/2008 | WO2008046003A2 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| 04/17/2008 | WO2008045998A2 Enantiomerically enriched iminopyrrolidone aziridine compositions |
| 04/17/2008 | WO2008045978A1 Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors |
| 04/17/2008 | WO2008045945A1 Benzindole derivatives and method of treating hiv/aids |
| 04/17/2008 | WO2008045860A2 Methods of inactivating viruses |
| 04/17/2008 | WO2008045852A2 Purification of streptococcus pneumoniae type 3 polysaccharides |
| 04/17/2008 | WO2008045817A2 Compositions for reducing nicotine withdrawal symptoms and/or tobacco usage |
| 04/17/2008 | WO2008045777A2 A process for the preparation of benzimidazole derivatives and their salts |
| 04/17/2008 | WO2008045739A1 Meal replacement compositions and weight control method |
| 04/17/2008 | WO2008045688A1 Chymase inhibitors |
| 04/17/2008 | WO2008045686A2 Enantiomerically enriched iminopyrrolidone azirdine compositions |
| 04/17/2008 | WO2008045664A2 Heterocyclic pde4 inhibitors as antiinflammatory agents |
| 04/17/2008 | WO2008045663A2 Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents |
| 04/17/2008 | WO2008045641A2 Composition s comprising a benzodiazepine, an alcohol aversive agent and an abuse aversive agent |
| 04/17/2008 | WO2008045627A2 Protein kinase inhibitors and methods for using thereof |